Hu Ning, Pang Yifan, Zhao Hongmian, Si Chaozeng, Ding Hui, Chen Li, Wang Chao, Qin Tong, Li Qianyu, Han Yu, Dai Yifeng, Zhang Yijie, Shi Jinlong, Wu Depei, Zhang Xinyou, Cheng Zhiheng, Fu Lin
Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China.
Department of Medicine, William Beaumont Hospital, Royal Oak, MI 48073, USA.
J Cancer. 2019 Oct 15;10(24):6088-6094. doi: 10.7150/jca.33244. eCollection 2019.
DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML). We first analyzed data of 85 AML patients who were treated with chemotherapy and had available DOCK1 to DOCK11 expression information and found that DOCK1 and DOCK2 had prognostic significance in AML. In view of the known prognosis of DOCK1 in AML, we then explored the prognostic role of DOCK2. One hundred fifty-six AML patients with DOCK2 expression data were extracted from The Cancer Genome Atlas (TCGA) database and enrolled in this study. Patients were divided based on treatment modality into the chemotherapy group and the allogeneic hematopoietic stem cell transplant (allo-HSCT) group. Each group was divided into two groups by the median expression levels of DOCK2. In the chemotherapy group, high DOCK2 expression was associated with longer event-free survival (EFS, =0.001) and overall survival (OS, =0.007). In the allo-HSCT group, EFS and OS were not significantly different between high and low DOCK2 expression groups. Multivariate analysis showed that high DOCK2 expression was an independent favorable prognostic factor for both EFS and OS in all patients (all <0.05). In conclusion, our results indicated that high DOCK2 expression, in contrast to DOCK1, conferred good prognosis in AML.
DOCK家族蛋白是Rho GTP酶在进化上保守的鸟嘌呤核苷酸交换因子，具有不同的细胞功能。已有研究表明，DOCK1在急性髓系白血病（AML）中具有不良预后作用。我们首先分析了85例接受化疗且有DOCK1至DOCK11表达信息的AML患者的数据，发现DOCK1和DOCK2在AML中具有预后意义。鉴于已知DOCK1在AML中的预后情况，我们随后探讨了DOCK2的预后作用。从癌症基因组图谱（TCGA）数据库中提取了156例有DOCK2表达数据的AML患者并纳入本研究。患者根据治疗方式分为化疗组和异基因造血干细胞移植（allo-HSCT）组。每组再根据DOCK2的中位表达水平分为两组。在化疗组中，DOCK2高表达与更长的无事件生存期（EFS，=0.001）和总生存期（OS，=0.007）相关。在allo-HSCT组中，DOCK2高表达组和低表达组的EFS和OS无显著差异。多因素分析表明，DOCK2高表达是所有患者EFS和OS的独立有利预后因素（均<0.05）。总之，我们的结果表明，与DOCK1相反，DOCK2高表达在AML中预示着良好的预后。
